AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00795132 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-Thymocyte Globulin
Description: Thymoglobulin will be administered at a dose of 2.5 mg/kg recipient body weight intravenously on each of 4 successive mornings (Days -4, -3,-2,-1) for patients receiving unrelated grafts and at a dose of 2.5mg/kg as a single dose on d-1 for patients receiving related marrow grafts. ATG is infused over a minimum of 4 hours, but is generally better tolerated over 6-8 hours. Suggested premedications are acetaminophen (10 mg/kg/dose), diphenhydramine (1 mg/kg/dose), and methylprednisolone. The methylprednisolone should be given at a dose of~1mg/kg 30 minutes prior to the ATG, with another 1mg /kg four hours into the infusion (total 2mg/kg/d). Patients are observed continuously for possible allergic reactions throughout the infusion.
Study NCT01752569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: The treatment schedule requires selumetinib to be taken either once daily at the same time each day or twice daily approximately 12 hours apart. Selumetinib should be taken with water at least 2 hours after a meal and 1 hour before the next meal. Selumetinib capsules will be administered in a continuous 21 day cycle (6 cycles), unless disease progression occurs.~For phase I there were 4 potential dosing levels:~Level -1 - 50mg once daily (od) (50mg daily total)~Level 1 (starting dose level for phase I) - 50mg bi-daily (bd) (100mg daily total)~Level 2 - 75mg bd (150mg daily total)~Level 3 - 100mg bd (200mg daily total)~Phase I has been completed and identified 75mg bd as the recommended phase II dose.~Phase II has begun and is utilising a dose of 75mg bd of selumetinib.
Study NCT01741194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-1204
Description: AC-1204 taken once daily, by mouth
Study NCT00795132 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine
Description: Administration and Dosage: Fludarabine will be administered at a dose of 30 mg/m2 in 100 ml of D5W intravenously over one hour on each of six consecutive days -10 through -5 for unrelated grafts or d-7 through d-2 for related grafts. Fludarabine is a fluorinated nucleotide analog of the antiviral agent vidarabine, 9-beta-D-arabinofuranosyladenine. Fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. The half-life of 2-fluoro-ara-A is approximately 10 hours. The mean total plasma clearance is 8.9 L/hr/m2 and the mean volume of distribution is 98 L/m2. Approximately 23% is excreted unchanged. This metabolite appears to act by inhibiting DNA polymerase alpha, ribonucleotide reductase and DNA primase, thus inhibiting DNA synthesis.
Study NCT01741194 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo taken once daily, by mouth
Study NCT00795132 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine
Description: Cyclosporine is a potent immunosuppressive agent that in animals prolongs survival of allogeneic transplants involving skin, kidney, liver, heart, pancreas, bone marrow, small intestine, and lung. The effectiveness of cyclosporine results from specific and reversible inhibition of immunocompetent lymphocytes in the G 0 - and G~1 -phase of the cell cycle. Administration and Dosage: Cyclosporin start on day -3 initially at a dose of 2.5mg/kg IV q12 hours or 3mg/kg/dose (neoral equivalent) PO q12 hours targeting suggested troughs of 250 to 350 ng/ml. Continuous infusion cyclosporin may be allowed per institutional preference. 3x daily dosing may be used for younger children to achieve therapeutic levels. PBMTC Protocol #ONC0313 19 Continuous infusion cyclosporin may be allowed per institutional preference.
Study NCT00795132 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil
Description: MMF is a potent, selective, uncompetitive, and reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH), and therefore inhibits the de novo pathway of guanosine nucleotide synthesis without incorporation into DNA. Administration and Dosage: Initial dosage will be IV or PO with switch to PO when tolerated. Starting doses will be 15 mg/kg/day bid (total dose 30mg/kg/d, IV same as PO dose) beginning day 0 with the first dose given approximately 4-6 hours after the stem cell infusion. This dose will stop on day +30 for patients receiving matched sibling BM/PBSC and UCB grafts, but will continue until day +40 and then taper at approximately 11%/wk over 8 weeks until patients are off at day +96.
Study NCT00046839 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT01664169 — intervention group
Intervention type: OTHER
Intervention: laboratory biomarker analysis
Study NCT04578418 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Hydrolyzed collagen
Description: Hydrolyzed collagen supplementation twice daily
Study NCT04578418 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Heavy slow resistance training
Description: Heavy slow resistance training 3 times weekly
Study NCT04578418 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heavy slow resistance training
Description: Heavy slow resistance training 3 times weekly
Study NCT02112162 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18
Description: Undergo FDG PET/MRI
Study NCT02112162 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Undergo FDG PET/MRI
Study NCT02112162 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: magnetic resonance imaging
Description: Undergo FDG PET/MRI
Study NCT00858403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Take tablets of Dasatinib by mouth once a day.
Study NCT00785135 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lenses containing prismatic correction
Description: The patient will receive lenses containing prismatic correction for heterophoria, as well as correction for hyperopia, myopia and astigmatism as indicated during initial examination.
Study NCT00785135 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Lenses not containing prismatic correction
Description: The patient will receive lenses containing correction for hyperopia, myopia and astigmatism as indicated during initial examination. The patient will not receive prismatic correction in these lenses.
Study NCT04578418 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo supplementation twice daily
Study NCT00005775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glutamine
Description: Infants randomized to glutamine supplementation will receive glutamine any time that parenteral nutrition is required during the first 120 days of hospitalization.
Study NCT00005775 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TrophAmine given any time that parenteral nutrition is required during the first 120 days of hospitalization.
Study NCT02008058 — intervention group
Intervention type: BEHAVIORAL
Intervention: Survey
Description: Patients will report pain and analgesic use through the automated telephone system, for 7 days in a row, once every 6 weeks. Data from diagnostic tests (CT Abdomen/Pelvis, Bone Scan, PSA, and circulating tumor cells) conducted during the study period will be collected from medical records by local personnel and entered into the secure online database quarterly, but no specific tests or schedules will be required in this observational study. Patients will remain on study for up to 26 months (slightly longer than the expected median survival in this population based on data from docetaxel, abiraterone, and MDV3100 pivotal phase 3 trials).
Study NCT04234243 — intervention group
Intervention type: PROCEDURE
Intervention: cytoreduction and HIPEC
Description: cytoreduction CCR 0-1, and HIPEC close technique
Study NCT04464941 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: a composite intervention with both group and individual components for oral health promotion program
Description: The group intervention consisted of:~1. Group oral health education 2. Display of Bass tooth-brushing methods 3. Broadcasting of songs as tooth-brushing reminders; The individual interventions included:~1. Instruction in the Bass tooth-brushing method, 2. Individual behavioral modification method
Study NCT06036030 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dihydroartemisinin
Description: dihidroartemisinin dose of 2-4 mg/Kg Body weight taken for 3 days
Study NCT06036030 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piperaquine
Description: piperaquine at a dose of 16-32 mg/Kg body weight taken for 3 days
Study NCT00601185 — intervention group
Intervention type: PROCEDURE
Intervention: confocal microscopy in vivo
Description: A dermatologist will perform a shave biopsy according to standard clinical procedures. This study will be carried out after the shave biopsy. The deep surface and the peripheral margins will be imaged on each patient.
Study NCT02112162 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03884920 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Polyherbal formulation
Description: Test candidate will be administered per oral before / with meal in two divided doses
Study NCT01674062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Loading dose 840 mg IV on Day 2 of Cycle 1, followed by 420 mg every 3 weeks thereafter, until disease progression or unacceptable toxicity.
Study NCT01674062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 2 mg/kg IV once weekly, or as 6 mg/kg every 3 weeks, beginning on Day 1 of Cycle 1 and on Day 1 of each 3-week cycle thereafter until disease progression or unacceptable toxicity.
Study NCT03902210 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Yoga
Description: 60 minutes per week of online yoga through Udaya.com
Study NCT03902210 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Podcast
Description: 60 minutes per week of podcasts
Study NCT06036030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine
Description: Primaquine dose 0.25 mg/kg body weight given to uncomplicated Plasmodium falciparum patients on the first day only
Study NCT06036030 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Primaquine
Description: Primaquine dose 0.25 mg/kg body weight given to uncomplicated Plasmodium falciparum patients on the first day only
Study NCT03264716 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HepaSphere TACE (transarterial chemoembolization)
Description: 100 mg doxorubicin will be loaded onto the HepaSphere Microspheres and delivered via microcatheter.
Study NCT02671058 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cortenema
Description: Hydrocortisone Administered as a Liquid Enema
Study NCT02671058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone Acetate
Description: Hydrocortisone Acetate Administered as a Suppository with the Sephure® Rectal Suppository Applicator
Study NCT01767753 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sensimed Triggerfish
Description: Portable investigational device using a contact lens sensor that monitors the IOP fluctuation continuously over 24-hours
Study NCT01517919 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-Led Self-Management
Description: The PLSM intervention is designed to improve and sustain participants' self-management and health-related gains associated with type 2 diabetes. The role of peer leaders is to provide support for (1) ongoing self-management efforts (including the 5-step action-planning process), (2) psychosocial and emotional adjustment, and (3) linkage to needed health care resources.~PLSM intervention will consist of three main components provided by the Peer Leaders: weekly self-management support sessions; outreach telephone contacts and inbound telephone call from participants.
Study NCT03866265 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Food Grade Extract of Salmon Polar Lipids (FGE-Salmon-PLs)
Description: Each participant will be administered per day a capsule of the FGE-Salmon-PLs food supplement (containing 0.125 g of FGE-Salmon-PLs) for a period of 28 days in a double blind randomized, crossover and placebo-controlled design.
Study NCT03866265 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each participant will be administered per day a placebo capsule (containing 0.125 g of glycerin) for a period of 28 days in a double blind randomized, crossover design.
Study NCT04477837 — intervention group
Intervention type: DRUG
Intervention: Apixaban 5 MG
Description: frequency of heavy menstrual bleeding
Study NCT04477837 — intervention group
Intervention type: DRUG
Intervention: Rivaroxaban 20 MG
Description: frequency of heavy menstrual bleeding
Study NCT04477837 — intervention group
Intervention type: DRUG
Intervention: Edoxaban 60 MG
Description: frequency of heavy menstrual bleeding
Study NCT04477837 — intervention group
Intervention type: DRUG
Intervention: Dabigatran 150 Mg Oral Capsule
Description: frequency of heavy menstrual bleeding
Study NCT02745600 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: RFA therapy simulator
Description: Computer assisted RFA of liver tumors: Planning, simulation, and follow up,
Study NCT06036030 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Momordica Charantia Extract
Description: Momordica charantia extract capsules at a dose of 325 mg were given to patients for 3 days
Study NCT04061161 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tiotropium Bromide
Description: Participants will be double-blind randomized for Tiotropium or Placebo treatment for 6 weeks
Study NCT03187951 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Assessments
Description: After completion of chemotherapy and/or radiation, 3-6 weeks after surgery, and then 3-7 months after surgery: Participant's hand grip strength measured using a hand-held machine. Participants arm strength measured using an arm curl test. Participants asked to rise from a chair without using their arms to push off. Participants complete a 6-minute walk test to see how far participant can walk in 6 minutes.
Study NCT04061161 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium Bromide
Description: Participants will be double-blind randomized for Tiotropium or Placebo treatment for 6 weeks
Study NCT03749356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TacroBell SR cap.
Description: * Orally, once-daily in the morning~* After first dose 0.2mg/kg, check the blood concentration of tacrolimus at each visit and adjust the dose to acheive the blood concentration maintaining at 3\~12ng/ml for 0 to 3months and then at 3\~8ng/ml for 3 to 6months of study treatment.
Study NCT02928822 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR-based sensorimotor aphasia therapy
Description: VR-based sensorimotor aphasia therapy. 8 weeks, 1 session a week, 30min-1h per session of language and motor therapy using using VR rehabilitation gaming system. The patients will play in pairs.
Study NCT02928822 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group (conventional aphasia rehabilitation)
Description: 8 weeks, 1 session a week, 30min-1h per session of conventional aphasia rehabilitation training the same vocabulary as the experimental group.
Study NCT02886689 — intervention group
Intervention type: DRUG
Intervention: TNF-alpha antagonist and other biotherapy
Study NCT02425644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ponesimod
Description: film-coated tablet with 20 mg ponesimod, administered orally once daily in the morning
Study NCT02425644 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: teriflunomide
Description: film-coated tablet with 14 mg teriflunomide, administered orally once daily in the morning
Study NCT02366598 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hemp shake
Description: Hemp protein shake
Study NCT02366598 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Soybean shake
Description: Soybean protein shake
Study NCT02133235 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional
Description: insertion endobronchial blocker with the guidance of fiberoptic bronchoscopy
Study NCT02133235 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: auscultation
Description: insertion endobronchial blocker by auscultation, without the guidance of fiberoptic bronchoscopy
Study NCT00872716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine XR
Description: 100 mg single-dose Quetiapine XR
Study NCT00872716 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02654327 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VV-ECCO2R to enable lower tidal volume mechanical ventilation
Description: In the intervention arm a dual lumen catheter will be inserted into a central vein. VV-ECCO2R is commenced and managed as per study manual. Tidal volumes are then reduced on mechanical ventilation to enable lower tidal volume ventilation. Lower tidal volume facilitated by VV-ECCO2R will continue for a least 2 days up to a maximum of 7 days
Study NCT01383200 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetracaine drop
Description: 0.5% Tetracaine Right eye / 2% Lidocaine Left eye
Study NCT00474188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-5013 (lenalidomide)
Description: Lenalidomide 25 mg, orally, once daily, on Days 1 to 21 of every 28-day cycle administerd in combination with dexamethasone 40 mg, orally, once daily, on Days 1, 8, 15, and 22 of every 28-day cycle
Study NCT00474188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Dexamethasone 40 mg, orally, once daily, on Days 1, 8, 15, and 22 of every 28-day cycle administered in combination with lenalidomide 25 mg, orally, once daily, on Days 1 to 21 of every 28-day cycle.
Study NCT03458845 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Computed Tomography Scan
Description: The results of the CT scan and the hand-grip test will be used for diagnosis of sarcopenia. The Royal Free Hospital-Global Assessment (RFH-GA) results will classify the nutritional status of the patient.
Study NCT00106106 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NMR-spectroscopy
Description: Scans were performed on a 3T scanner using the echo-time-averaged PRESS sequence previously published to detect glutamate's resonance line at 2.35 ppm and average out the interferences from glutamine, NAA and the macromolecules.
Study NCT00106106 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: NMR-spectroscopy
Description: Scans were performed on a 3T scanner using the echo-time-averaged PRESS sequence previously published to detect glutamate's resonance line at 2.35 ppm and average out the interferences from glutamine, NAA and the macromolecules.
Study NCT00106106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral acamprosate
Description: For subjects randomized to active treatment, the first 3 acamprosate doses were 1332 mg every 8 hours in an attempt to more rapidly achieve active plasma concentrations, followed by 666 mg acamprosate every 8 hours for the remainder of the study.
Study NCT00338390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abacavir
Description: Change tenofovir to abacavir
Study NCT00338390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Didanosine
Description: Increase didanosine dose to 400 mg/day if weight is > 60 Kg. or to 250mg/day if weight is \< 60 kg.
Study NCT00338390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abacavir+Lamivudine
Description: Change tenofovir and didanosine to abacavir + lamivudine (600mg+300 mg/day in one single tablet).
Study NCT01437735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAW039
Description: QAW039 po
Study NCT02366598 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soybean shake
Description: Soybean protein shake
Study NCT02366598 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Non-protein shake
Study NCT01437735 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast
Description: Montelukast 10 mg po
Study NCT01437735 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01769222 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given intratumorally
Study NCT01823510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor + Aspirin
Description: Single loading doses of Ticagrelor (180 mg) and ASA (325 mg), followed by daily dosing for 5-7 days (ticagrelor 90 mg twice daily + ASA 81 mg once daily).
Study NCT01823510 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel + Aspirin
Description: Single loading doses of Clopidogrel (600 mg) and ASA (325 mg), followed by daily dosing for 5-7 days (clopidogrel 75 mg + ASA 81 mg once daily).
Study NCT01927302 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment Focusing on Naming Objects
Description: Treatment will be administered from week 0 until week 12.
Study NCT01927302 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment Focusing on Improving Spelling Abilities
Description: Treatment will be administered from week 0 until week 12.
Study NCT01927302 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment Focusing on Improving Sentence Processing
Description: Treatment will be administered from week 0 until week 12.